Jamjoom Pharma’s bold rebrand is propelling the company into its next era of innovation and global expansion, positioning it as a driving force in redefining healthcare.
In an industry where science, trust, and access intersect, Jamjoom Pharma has unveiled a new corporate identity that speaks as much to its ambitions as to its legacy. The rebrand is more than a visual shift; it is a strategic signal that the Saudi-headquartered pharmaceutical company is accelerating toward a future defined by innovation, patient access, and global competitiveness.
Founded in 2000, Jamjoom Pharma has grown into one of the region’s fastest-expanding pharma players, with operations spanning more than 36 countries across the Middle East and Africa.
From regional champion to global contender
The refreshed brand identity marks a decisive step in Jamjoom Pharma’s journey from a trusted regional manufacturer into a contender on the global stage. Its leadership emphasizes that the company’s focus is not only on expanding product lines but also on shaping healthcare ecosystems; strengthening infrastructure, ensuring affordability, and bringing innovative therapies to high-prevalence therapeutic areas.
“Healthcare is not just about delivering medicines; it’s about creating sustainable systems where patients consistently have access to quality solutions,” says Dr. Tarek Hosni, CEO of Jamjoom Pharma. “Our new identity reflects that mission— anchored in care, yet focused to carry our global aspirations.”
Numbers that tell a story of momentum
A little over two years ago, Jamjoom Pharma made its debut on the Saudi Exchange with a valuation of $1.1 billion. Today, the company’s market capitalization has surged to $2.9 billion—nearly tripling in value. This remarkable ascent stands as a testament to the unwavering confidence of its shareholders and the company’s steadfast commitment to delivering sustained value, innovation, and growth in one of the region’s most dynamic sectors.
Behind these figures is a pipeline that continues to expand. With recent launches in ophthalmology, anti-diabetics, and pain management, the company now manages a portfolio of 147 active brands. It is investing in both established and emerging therapeutic areas, positioning itself to meet the region’s most urgent health needs.
A brand with purpose
What makes Jamjoom Pharma’s rebrand distinctive is its grounding in patient-centric values. The company has long embraced the principle of “quality without compromise,” a promise that resonates in markets where access gaps remain a daily reality. By leveraging four stateof-the-art manufacturing facilities across MEA, the company ensures that production and distribution keep pace with demand.
This alignment with Saudi Arabia’s Vision 2030 is intentional. As the kingdom drives reforms to strengthen healthcare access and outcomes, Jamjoom Pharma’s strategy dovetails with national ambitions—localizing production, scaling innovation, and reinforcing regional supply chains.
Looking ahead
As competition in the pharmaceutical industry intensifies, Jamjoom Pharma’s sharpened identity provides clarity: it intends to lead with both impact and intent. The company is investing in talent, partnerships, and R&D capacity, while reinforcing its reputation as a reliable regional partner for governments, healthcare providers, and patients.
In Dr. Hosni’s words, “Every community we touch deserves better health. That’s the ultimate purpose behind our evolution—and the future we are building.
